The World Health Organization has issued its first guidelines specifically for the diagnosis and management of type 1 diabetes in adults, including recommendations for healthcare systems with limited resources.
The guidelines were released on November 14, World Diabetes Day.
WHO estimates that approximately 9.5 million people worldwide were living with type 1 diabetes in 2025, with around 500,000 additional people diagnosed during that year.
Insulin remains central to treatment
Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin.
People with the condition depend on insulin treatment to survive.
The new guidelines recommend multiple daily insulin injections, with doses adjusted according to blood glucose levels.
WHO identifies human insulin as an effective treatment option and recognises that other insulin types may be used when appropriate.
Guidance addresses limited access to testing
The organisation recommends regular monitoring of blood glucose.
At home, this may involve finger-prick tests or continuous glucose monitoring devices. Clinics can use laboratory tests to assess average blood glucose levels over previous months.
Where blood glucose testing is unavailable, WHO says urine glucose testing may be considered.
The guidance also covers emergency and humanitarian settings where normal health services may be disrupted.
Access remains a major concern
More than a century after insulin was discovered, many patients still struggle to obtain affordable treatment.
WHO’s 2030 objectives include access to affordable insulin and blood glucose self-monitoring for everyone living with type 1 diabetes.
The November 14 announcement does not provide country-by-country estimates of insulin availability or the number of patients unable to afford treatment.
Those data would be necessary to assess how far individual health systems remain from the WHO objectives.
New recommendations require national implementation
The guidelines provide clinical recommendations for health authorities and practitioners.
They do not automatically change national treatment protocols, medicine prices or insurance coverage.
WHO says it will provide tools to support implementation and monitor progress.
Health authorities will need to determine how the recommendations fit their existing treatment programmes and available resources.
World Health Organization, 14 November 2026

















